Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
Blood Advances|May 10, 2023
The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project NetworkGreg Hapgood, Monica Civallero, Yana Stepanishyna, et al.Hemasphere|October 15, 2021
Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma AllianceStephen Boyle, Joshua W D Tobin, Jacinta Perram, et al.Hematological Oncology|April 16, 2019
A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphomaZi Yun Ng, Mark Bishton, David Ritchie, et al.Haematologica|February 23, 2023
Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma AllianceAllison Barraclough, James T England, Diego Villa, et al.The New England Journal of Medicine|December 14, 2021
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell LymphomaHervé Tilly, Franck Morschhauser, Laurie H Sehn, et al.Blood Neoplasia|June 24, 2025
Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapyJoshua W D Tobin, Venkata A Chikatamarla, Marko Matic, et al.Internal Medicine Journal|May 17, 2020
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemicPietro Di Ciaccio, Georgia McCaughan, Judith Trotman, et al.Internal Medicine Journal|May 28, 2021
COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statementGeorgia McCaughan, Pietro Di Ciaccio, Michelle Ananda-Rajah, et al.Blood Advances|October 2, 2019
Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma AllianceJoshua W D Tobin, Gabrielle Rule, Katherine Colvin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2026
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter AnalysisMatthew R Wilson, Katharine L Lewis, Amy A Kirkwood, et al.Pageof 4